After 24 h medium was discarded as recommended in [9] and 110 l medium without CuCl 2 or CuSO 4 containing 10 l CCK-8 Solution was added
Exploring oxidative stress in disease and its connection with adenosine
DISSECTION P938 - ESOC25-2421 CADASIL Argentine Registry (CADASILar): Establishing a Harmonized Clinical Protocol preliminary data Julieta Rosales 1 , Carolina Ardohain 2 , Juan Lopez 3 , Fabio Gonzalez 4 , Julian Alonso 5 , Valentin Selvaggi 6 , Diana Cristalli 7 , Ismael Calandri 2 1 Clinica Sagrada Familia-ENERI, Buenos Aires, Argentina, 2 FLENI, Buenos Aires, Argentina, 3 Sanatorio Los Arcos, Buenos Aires, Argentina, 4 Hospital Italiano de Bs As, Buenos Aires, Argentina, 5 Hospital Posadas, Buenos Aires, Argentina, 6 Hospital Ramos Meja, Buenos Aires, Argentina, 7 Centro Jesi, Buenos Aires, Argentina Background and Aims: CADASIL, a leading monogenic small vessel disease caused by NOTCH3 mutations, manifests with migraines, strokes, and cognitive decline
Cluster 1 had the highest mortality risk (HR 2.03, 95% CI 1.552.67, p 25cm HO
CB-12 Injection is administered via an intramuscular or slow intravenous route
What the Human Evidence Actually Shows Sadly, we currently dont have massive Phase 3 trials comparing GHK-Cu head-to-head with Finasteride in 5,000 men
